Haemonetics Corporation (HAE) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Total Assets Chart for Haemonetics Corporation
Haemonetics Corporation (HAE) total assets for FY2026 were USD 2.4B, a -2.2% change from FY2025. Haemonetics Corporation's total assets grew from USD 144.8M in 1992 to USD 2.4B in 2026 (1554.6% over 34 years). Total assets compound annual growth rate: 5-year CAGR of 5.7%, 10-year CAGR of 6.2%, 20-year CAGR of 7.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $4.71B
- Implied Share Price
- $103.52
- Enterprise Value
- $5.81B
- Revenue (TTM)
- $1.35B
- EBITDA
- $358.79M
- Profit Margin
- 7.12%
- Trailing P/E
- 50.01
- Forward P/E
- 20.33
- Price/Book (MRQ)
- 5.81
- Price/Sales (TTM)
- 3.48
- EV/EBITDA
- 9.36
- EV/Revenue
- 4.30
- Dividend Yield
- —
- Book Value
- $18.41
- Free Cash Flow (FY2026)
- $260.44M
- Free Cash Flow Yield
- 5.53%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.